Paxlovid approved as first oral drug for COVID-19

Pfizer increases Paxlovid production capacity

Ten post jest także dostępny w języku: polski

Paxlovid, a Pfizer-developed anti-covid medicine that is the first anti-covid treatment licensed in the United States in oral tablet form, received emergency approval from the US Food and Drug Administration (FDA). Paxlovid was licensed by the Medicines and Healthcare Products Regulatory Agency (MHRA) in London shortly after. The first supply of the medication recently arrived in Izrael.

According to the FDA, the medicine is approved for use in individuals who are in the early stages of the disease and is not designed for use in hospitalized patients, as a preventative measure, or as a vaccination substitute. The medicine has been also approved by the Medicines and Healthcare Products Regulatory Agency (MHRA) for treatment in adult patients with mild to moderate Covid-19 symptoms who are at risk of a severe illness transition. Paxlovid is an oral medication that should be taken within five days after the beginning of symptoms.

Clinical studies showed that the medicine was 88 percent effective in reducing hospitalization and mortality in vulnerable people who started therapy within five days of symptom onset. This led to the decision to approve the drug. The medicine package contains ten tablets of nirmatrelvir, a viral replication inhibitor, and twenty tablets of ritonavir, a prolonger of the primary agent. The FDA recommends taking two ritonavir pills and one nirmatrelvir tablet twice day for five days.

Paxlovid was licensed for use in the United States and Japan, among other nations, in December. In mid-December, the European Medicines Agency (EMA) issued an emergency use recommendation, but the medicine was not allowed to be widely marketed. The pre-authorization suggestions, according to the EMA, are designed to be used by regulators in EU nations to determine whether or not to approve therapy with the medicine prior to final approval.

Among others, the first shipment of Pfizer’s anti-Covid tablet arrived in Israel on 30 December, with Prime Minister Naftali Bennett praising it as crucial in the face of an increase in cases caused by the highly contagious Omicron form.

On Tuesday, the Ministry of Health reported 11,670 new coronavirus infections in Poland. A total of 433 people have died as a result of COVID-19, with over 320 of them being unvaccinated. On 28 December, a week ago, there were 9,843 new illnesses and 549 fatalities reported. This translates to an 18% rise in infection rates.

Similar Posts